3648 results for «2580»
3648 results
Ascending into the future with drug-coated balloons
21 May 2026 – From EuroPCR 2026
Step into the future of interventional cardiology with comprehensive insights into drug‑coated balloons (DCB). This session covers the new DCB ARC guidelines, previews findings from the impactful BASKET BALL randomised trial, and examines real-world evidence from the SCORE registry. It also addresses the optimisation of acute...
IVUS and NIRS imaging: a pathway to improve outcomes in stable and acute coronary syndromes
19 May 2026 – From EuroPCR 2026
IVUS-guided PCI is well established in complex coronary interventions, but combining it with near-infrared spectroscopy (NIRS) is opening a new dimension by linking vessel geometry with plaque biology.
This EuroPCR 2026session explores how IVUS-NIRS imaging improves PCI planning and risk stratification in both stable and acute coronary...
Managing life-threatening TAVI complications
19 May 2026 – From EuroPCR 2026
Manage life-threatening complications in TAVI procedures with a structured algorithm for identification and resolution. This session shares expert tips for handling specific severe complications and reviews best practices aimed at complication avoidance to enhance patient safety and procedural success.
Artificial intelligence-powered precision: CT-guided PCI and the future of image-guided therapy
19 May 2026 – From EuroPCR 2026
Image-guided PCI is entering a new era, driven by artificial intelligence and advanced CT technologies that are reshaping how coronary interventions are planned and performed.
This EuroPCR 2026 session explores the integration of photon-counting CT into PCI workflows, highlighting its improved spatial resolution, enhanced plaque characterisation and...
DCB: does coating morphology matter for distal embolisation and clinical outcomes?
20 May 2026 – From EuroPCR 2026
Drug-coated balloon (DCB) therapy continues to evolve, with increasing attention on how coating design may influence drug transfer, vessel response and downstream clinical outcomes.
This EuroPCR 2026 session examines the role of coating morphology, comparing amorphous and crystalline technologies and their implications for drug delivery efficiency and...
All we need to know about vulnerable plaque
19 May 2026 – From EuroPCR 2026
Understand the critical importance of vulnerable plaque identification and management. This session covers optimal strategies for detecting vulnerable plaques, their prognostic implications, and evidence-based treatment approaches illustrated through detailed case presentations.
Next generation TAVI procedural planning
19 May 2026 – From EuroPCR 2026
Explore the forefront of TAVI procedural planning, featuring innovations such as valve-in-valve techniques for sutureless valves, integration of artificial intelligence in heart team decisions, and advanced imaging-guided access methods. The session also examines clinical outcomes related to bicuspid anatomy and prosthesis-patient mismatch, providing a comprehensive view...
MagicTouch sirolimus-coated balloon for coronary artery disease and peripheral artery disease treatment: where evidence meets experience
20 May 2026 – From EuroPCR 2026
This session examines the clinical evidence and experiential insights regarding the MagicTouch sirolimus-coated balloon (SCB) for treating coronary and peripheral artery disease. It reviews long-term comparative data versus paclitaxel-coated balloons, application techniques, integration into current practices, and findings from major trials such as SIRONA and SIMPLE-DM,...
Selecting PCI devices in specific scenarios
19 May 2026 – From EuroPCR 2026
This session addresses device selection strategies tailored to specific interventional cardiology scenarios. It covers innovative approaches such as coronary laser use in difficult lesions, intravascular imaging-guided treatments for in-stent restenosis, and physiological assessment post-magnesium scaffold resorption, supported by real-world data and emerging machine learning applications.
Angiography-based physiology: time to change your routine clinical practice?
20 May 2026 – From EuroPCR 2026
This session offers a critical appraisal of angiography-based physiology, with a focus on virtual fractional flow reserve (vFFR) technology. It reviews the latest clinical evidence, including insights from the FAST study programme and the FAST III randomised controlled trial. Gain a clear understanding of current guideline...
Beyond visualisation: the value and future of 4D intracardiac echocardiography in tricuspid repair and replacement
20 May 2026 – From EuroPCR 2026
Explore the transformative role of 4D intracardiac echocardiography in guiding tricuspid edge-to-edge repair (TEER) and valve replacement for tricuspid regurgitation. This session highlights how real-time, high-resolution imaging enhances procedural efficiency and safety, reducing reliance on general anesthesia and shortening procedure times compared to traditional imaging modalities.
New evidence in the treatment of calcified lesions
19 May 2026 – From EuroPCR 2026
This session presents the latest evidence on treating calcified coronary lesions, comparing intravascular lithotripsy, cutting balloons, rotational and orbital atherectomy. It includes clinical trial data on efficacy, safety, and impact on coronary microvascular function, providing a robust foundation for evidence-based decision-making in calcified lesion management.
Where to leave less behind: non-invasive CT and angiography-derived physiology for DCB lesion selection
20 May 2026 – From EuroPCR 2026
This session elucidates the role of non-invasive coronary CT and angiography-derived physiology in guiding lesion selection for drug-eluting balloon PCI. It emphasises integrating anatomical and physiological data to refine lesion preparation, strategy, and validation beyond angiography, and identifies scenarios where DEB PCI may not be optimal,...
TAVI procedural complications - Part 1: VSD, valve embolisation, and more
19 May 2026 – From EuroPCR 2026
This session focuses on the complex complications that can arise during TAVI procedures, such as ventricular septal defects, valve embolisation, and other critical events. Through detailed case analyses, it offers strategies for recognition, prevention, and management to improve patient safety and outcomes.
Reshaping what's possible in complex PCI with advanced sirolimus technology
21 May 2026 – From EuroPCR 2026
Focused on advancing complex PCI, this session explores strategies to minimise metal use through advanced sirolimus technologies and drug-coated balloon (DCB) therapies. It highlights the biological and pharmacokinetic characteristics of DCBs, key device design considerations, and practical approaches to less-metal PCI. Clinical cases illustrate challenges such...
Behind standard practice: a place for DCB
19 May 2026 – From EuroPCR 2026
This session examines the role of drug-coated balloons (DCB) beyond standard practice in coronary revascularization. It includes discussions on revascularization strategies in young patients, rescue of early distal LIMA–LAD anastomosis, treatment of in-stent restenosis, stepwise complex CTO bifurcation revascularization using kissing DCBs, and management of calcified...
Re-intervention challenges after first aortic valve replacement
19 May 2026 – From EuroPCR 2026
Addressing the challenges of re-intervention after initial aortic valve replacement, this session highlights advanced valve-in-valve TAVI strategies, including leaflet modification techniques, management of extreme coronary obstruction risks, and complex anatomical considerations such as post-Bentall root anatomy.
CTO PCI: how to prevent and manage complications effectively?
19 May 2026 – From EuroPCR 2026
Focused on chronic total occlusion (CTO) PCI, this session highlights the critical importance of procedural planning to minimize complications. Through detailed case analyses of coronary dissection and perforation, it outlines early identification strategies and equips clinicians with essential tools and techniques for effective complication management in...
New evidence for pharmacology for coronary artery disease
19 May 2026 – From EuroPCR 2026
This session presents the latest evidence in pharmacological management of coronary artery disease, featuring pivotal trials such as VESALIUS-CV and TARGET FIRST. It covers topics including evolocumab efficacy post-stenting, early aspirin cessation strategies, aspirin-free protocols after complex PCI in ACS, and comparative outcomes of clopidogrel versus...
Bioresorbable devices in clinical practice
19 May 2026 – From EuroPCR 2026
This session examines the evolving role of bioresorbable devices in coronary intervention, showcasing hybrid PCI strategies, novel applications in myocardial bridging, and innovative solutions for complex coronary lesions, including the use of bioadaptors and dual-device techniques.